Clot-targeting the novel thrombolytic activity of recombinant factor X

While blood clotting is essential for life, too much clot results in heart disease and stroke. The Pryzdial Lab discovered that the plasma protein, clotting factor X (FX), can also dissolve clots and converted this new function into a stable clot-dissolving agent called Xai-K. We are aiming to translate Xai-K into a therapeutic that restores the normal passage of blood and save lives. While the current clot-dissolving drugs have helped many people, they are not perfect. The biggest problem is that up to 7% of patients may suffer bleeding. Addressing this life-threatening problem, we reported that Xai-K was more effective than the standard clot-dissolving therapeutic (tPA) using animal models. Furthermore, measurements of bleeding risk throughout the body indicated that Xai-K was safer than tPA and in our pilot data also safer when measured directly in the brain, where safety risk is greatest. The current project focuses on generating a version of Xai-K that is easier to produce and to understand how it is safer. This recombinant replacement has been created and proven effective in test experiments. We will continue to develop and evaluate this new clot-buster, advancing toward a safer life-saving medicine.

PRYZDIAL, Ed

University of British Columbia

Postdoctoral Fellowship Program

British Columbia

$164,200